PMC:7242007 / 3325-3544 JSONTXT

Annnotations TAB JSON ListView MergeView

11 noted a background HBV prevalence rate of 6.5% (2/31) while reporting on their experience with the use of corticosteroids in COVID‐19; further, they observed delayed SARS‐CoV‐2 clearance in those with HBV infection.